

January 4, 2021

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Deanna Virginio

**Re: Prelude Therapeutics Incorporated**  
**Registration Statement on Form S-1 (File No. 333-251874)**  
**Request for Acceleration**

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:30 p.m. Eastern Time, on Wednesday, January 6, 2020 or as soon thereafter as practicable.

*[Signature page follows]*

---

Very truly yours,

Morgan Stanley & Co. LLC  
Goldman Sachs & Co. LLC  
BofA Securities, Inc.

As representatives of the Underwriters

By: Morgan Stanley & Co. LLC

By: /s/ Chris Rigoli

\_\_\_\_\_  
Name: Chris Rigoli  
Title: Vice President

By: Goldman Sachs & Co. LLC

By: /s/ Elizabeth Wood

\_\_\_\_\_  
Name: Elizabeth Wood  
Title: Managing Director

By: BofA Securities, Inc.

By: /s/ Greg Butz

\_\_\_\_\_  
Name: Greg Butz  
Title: Managing Director

[Signature Page to Prelude Therapeutics Incorporated Acceleration Request]